CREG1 enhances p16INK4a-induced cellular senescence

Cell Cycle

Volumn 10, Issue 3, 2011, Pages 518-530

  Moolmuang, Benchamart ^a   Tainsky, Michael A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cellular immortalization; Cellular senescence; CREG1; Li Fraumeni syndrome

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GENE PRODUCT; MESSENGER RNA; PROTEIN CREG1; RETINOBLASTOMA PROTEIN; TUBULIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL AGING; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL STRESS; CELL TRANSFORMATION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; FAMILIAL CANCER; FIBROBLAST; FIBROSARCOMA; HUMAN; HUMAN CELL; OSTEOSARCOMA CELL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SENESCENCE; TELOMERE;

EID: 79851500885     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.3.14756     Document Type: Article

References (44)

1. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965; 37:614-36.
2. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995; 92:9363-7.
3. Campisi J, d'Adda di Fagagna F. Cellular senescence: When bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8:729-40.
4. Shay JW, Pereira-Smith OM, Wright WE. A role for both RB and p53 in the regulation of human cellular senescence. Exp Cell Res 1991; 196:33-9. (Pubitemid 121006368)
5. Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D, Barrett JC. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci USA 1996; 93:13742-7. (Pubitemid 26424190)
6. Hara E, Smith R, Parry D, Tahara H, Stone S, Peters G. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol 1996; 16:859-67.
7. Stein GH, Drullinger LF, Soulard A, Dulic V. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol Cell Biol 1999; 19:2109-17. (Pubitemid 29098269)
8. Medema RH, Herrera RE, Lam F, Weinberg RA. Growth suppression by p16ink4 requires functional retinoblastoma protein. Proc Natl Acad Sci USA 1995; 92:6289-93.
9. Dai CY, Enders GH. p16INK4a can initiate an autonomous senescence program. Oncogene 2000; 19:1613-22. (Pubitemid 30200963)
10. Rountree MR, Bachman KE, Herman JG, Baylin SB. DNA methylation, chromatin inheritance and cancer. Oncogene 2001; 20:3156-65. (Pubitemid 32553571)
11. Haaf T. The effects of 5-azacytidine and 5-azadeoxycytidine on chromosome structure and function: implications for methylation-associated cellular processes. Pharmacol Ther 1995; 65:19-46. (Pubitemid 24381835)
12. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer and other neoplasms. A familial syndrome? Ann Intern Med 1969; 71:747-52.
13. Chompret A. The Li-Fraumeni syndrome. Biochimie 2002; 84:75-82. (Pubitemid 34477095)
14. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 1990; 250:1233-8. (Pubitemid 120031831)
15. Bischoff FZ, Strong LC, Yim SO, Pratt DR, Siciliano MJ, Giovanella BC, Tainsky MA. Tumorigenic transformation of spontaneously immortalized fibroblasts from patients with a familial cancer syndrome. Oncogene 1991; 6:183-6. (Pubitemid 21902661)
16. Bischoff FZ, Yim SO, Pathak S, Grant G, Siciliano MJ, Giovanella BC, et al. Spontaneous abnormalities in normal fibroblasts from patients with Li-Fraumeni cancer syndrome: Aneuploidy and immortalization. Cancer Res 1990; 50:7979-84.
17. Fridman AL, Tang L, Kulaeva OI, Ye B, Li Q, Nahhas F, et al. Expression profiling identifies three pathways altered in cellular immortalization: interferon, cell cycle and cytoskeleton. J Gerontol A Biol Sci Med Sci 2006; 61:879-89. (Pubitemid 44413926)
18. Vogt M, Haggblom C, Yeargin J, Christiansen-Weber T, Haas M. Independent induction of senescence by p16INK4a and p21CIP1 in spontaneously immortalized human fibroblasts. Cell Growth Differ 1998; 9:139-46. (Pubitemid 128472554)
19. Kulaeva OI, Draghici S, Tang L, Kraniak JM, Land SJ, Tainsky MA. Epigenetic silencing of multiple interferon pathway genes after cellular immortalization. Oncogene 2003; 22:4118-27. (Pubitemid 36819652)
20. Veal E, Eisenstein M, Tseng ZH, Gill G. A cellular repressor of E1A-stimulated genes that inhibits activation by E2F. Mol Cell Biol 1998; 18:5032-41. (Pubitemid 28388086)
21. Sacher M, Di Bacco A, Lunin VV, Ye Z, Wagner J, Gill G, et al. The crystal structure of CREG, a secreted glycoprotein involved in cellular growth and differentiation. Proc Natl Acad Sci USA 2005; 102:18326-31. (Pubitemid 43011225)
22. Veal E, Groisman R, Eisenstein M, Gill G. The secreted glycoprotein CREG enhances differentiation of NTERA-2 human embryonal carcinoma cells. Oncogene 2000; 19:2120-8. (Pubitemid 30251377)
23. Di Bacco A, Gill G. The secreted glycoprotein CREG inhibits cell growth dependent on the mannose-6-phosphate/ insulin-like growth factor II receptor. Oncogene 2003; 22:5436-45. (Pubitemid 37072198)
24. Han YL, Guo P, Sun MY, Guo L, Luan B, Kang J, et al. Secreted CREG inhibits cell proliferation mediated by mannose 6-phosphate/insulin-like growth factor II receptor in NIH3T3 fibroblasts. Genes Cells 2008; 13:977-86.
25. Han Y, Deng J, Guo L, Yan C, Liang M, Kang J, et al. CREG promotes a mature smooth muscle cell phenotype and reduces neointimal formation in balloon-injured rat carotid artery. Cardiovasc Res 2008; 78:597-604. (Pubitemid 351769765)
26. Han Y, Guo L, Yan C, Guo P, Deng J, Mai X, et al. Adenovirus-mediated intra-arterial delivery of cellular repressor of E1A-stimulated genes inhibits neointima formation in rabbits after balloon injury. J Vasc Surg 2008; 48:201-9.
27. Bian Z, Cai J, Shen DF, Chen L, Yan L, Tang Q, et al. Cellular repressor of E1A-stimulated genes attenuates cardiac hypertrophy and fibrosis. J Cell Mol Med 2008; 13:1302-13.
28. Han Y, Cui J, Tao J, Guo L, Guo P, Sun M, et al. CREG inhibits migration of human vascular smooth muscle cells by mediating IGF-II endocytosis. Exp Cell Res 2009; 315:3301-11.
29. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001; 10:687-92. (Pubitemid 32331576)
30. Janderova-Rossmeislova L, Novakova Z, Vlasakova J, Philimonenko V, Hozak P, Hodny Z. PML protein association with specific nucleolar structures differs in normal, tumor and senescent human cells. J Struct Biol 2007; 159:56-70. (Pubitemid 46880553)
31. Paulson TG, Almasan A, Brody LL, Wahl GM. Gene amplification in a p53-deficient cell line requires cell cycle progression under conditions that generate DNA breakage. Mol Cell Biol 1998; 18:3089-100. (Pubitemid 28183477)
32. Hensler PJ, Annab LA, Barrett JC, Pereira-Smith OM. A gene involved in control of human cellular senescence on human chromosome 1q. Mol Cell Biol 1994; 14:2291-7. (Pubitemid 24108210)
33. Rogan EM, Bryan TM, Hukku B, Maclean K, Chang AC, Moy EL, et al. Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol Cell Biol 1995; 15:4745-53.
34. Craig C, Kim M, Ohri E, Wersto R, Katayose D, Li Z, et al. Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells. Oncogene 1998; 16:265-72. (Pubitemid 28045113)
35. Mitra J, Dai CY, Somasundaram K, El-Deiry WS, Satyamoorthy K, Herlyn M, et al. Induction of p21(WAF1/CIP1) and inhibition of Cdk2 mediated by the tumor suppressor p16(INK4a). Mol Cell Biol 1999; 19:3916-28. (Pubitemid 29193851)
36. Helmbold H, Komm N, Deppert W, Bohn W. Rb2/ p130 is the dominating pocket protein in the p53-p21 DNA damage response pathway leading to senescence. Oncogene 2009; 28:3456-67.
37. Kapic A, Helmbold H, Reimer R, Klotzsche O, Deppert W, Bohn W. Cooperation between p53 and p130(Rb2) in induction of cellular senescence. Cell Death Differ 2006; 13:324-34. (Pubitemid 43102215)
38. Jackson JG, Pereira-Smith OM. Primary and compensatory roles for RB family members at cell cycle gene promoters that are deacetylated and downregulated in doxorubicin-induced senescence of breast cancer cells. Mol Cell Biol 2006; 26:2501-10.
39. Lacy S, Whyte P. Identification of a p130 domain mediating interactions with cyclin A/cdk 2 and cyclin E/cdk 2 complexes. Oncogene 1997; 14:2395-406. (Pubitemid 27268158)
40. Kornfeld S. Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. Annu Rev Biochem 1992; 61:307-30.
41. Schmittgen TD, Zakrajsek BA, Mills AG, Gorn V, Singer MJ, Reed MW. Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. Anal Biochem 2000; 285:194-204.
42. Li Q, Tang L, Roberts PC, Kraniak JM, Fridman AL, Kulaeva OI, et al. Interferon regulatory factors IRF5 and IRF7 inhibit growth and induce senescence in immortal Li-Fraumeni fibroblasts. Mol Cancer Res 2008; 6:770-84.
43. Ahmed-Choudhury J, Agathanggelou A, Fenton SL, Ricketts C, Clark GJ, Maher ER, Latif F. Transcriptional regulation of cyclin A2 by RASSF1A through the enhanced binding of p120E4F to the cyclin A2 promoter. Cancer Res 2005; 65:2690-7. (Pubitemid 40490069)
44. Doerksen LF, Bhattacharya A, Kannan P, Pratt D, Tainsky MA. Functional interaction between a RARE and an AP-2 binding site in the regulation of the human HOX A4 gene promoter. Nucleic Acids Res 1996; 24:2849-56. (Pubitemid 26239759)